JP7093306B2 - ＰＤＥ１阻害剤としての１，５－ジヒドロ－４Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－４－オン及び１，５－ジヒドロ－４Ｈ－ピラゾロ［４，３－ｃ］ピリジン－４－オン - Google Patents
ＰＤＥ１阻害剤としての１，５－ジヒドロ－４Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－４－オン及び１，５－ジヒドロ－４Ｈ－ピラゾロ［４，３－ｃ］ピリジン－４－オン Download PDFInfo
- Publication number
- JP7093306B2 JP7093306B2 JP2018550733A JP2018550733A JP7093306B2 JP 7093306 B2 JP7093306 B2 JP 7093306B2 JP 2018550733 A JP2018550733 A JP 2018550733A JP 2018550733 A JP2018550733 A JP 2018550733A JP 7093306 B2 JP7093306 B2 JP 7093306B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrazolo
- pyridin
- tetrahydropyran
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201600221 | 2016-04-12 | ||
| DKPA201600221 | 2016-04-12 | ||
| PCT/EP2017/058332 WO2017178350A1 (en) | 2016-04-12 | 2017-04-07 | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517996A JP2019517996A (ja) | 2019-06-27 |
| JP2019517996A5 JP2019517996A5 (https=) | 2020-05-07 |
| JP7093306B2 true JP7093306B2 (ja) | 2022-06-29 |
Family
ID=58489694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550733A Expired - Fee Related JP7093306B2 (ja) | 2016-04-12 | 2017-04-07 | ＰＤＥ１阻害剤としての１，５－ジヒドロ－４Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－４－オン及び１，５－ジヒドロ－４Ｈ－ピラゾロ［４，３－ｃ］ピリジン－４－オン |
Country Status (43)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| ES2967489T3 (es) | 2016-10-18 | 2024-04-30 | H Lundbeck As | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 |
| RU2019109039A (ru) | 2016-10-28 | 2020-11-30 | Х. Лундбекк А/С | Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов, предназначенные для лечения психических и/или когнитивных расстройств |
| MX2019004859A (es) | 2016-10-28 | 2019-06-20 | H Lundbeck As | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. |
| JP7111720B2 (ja) | 2016-12-28 | 2022-08-02 | ダート・ニューロサイエンス・エルエルシー | Ｐｄｅ２阻害剤としての置換ピラゾロピリミジノン化合物 |
| CA3120971A1 (en) | 2017-11-27 | 2019-05-31 | Dart Neuroscience, Llc | Substituted furanopyrimidine compounds as pde1 inhibitors |
| AU2019275453B2 (en) | 2018-05-25 | 2023-12-21 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2020210614A1 (en) | 2019-04-12 | 2020-10-15 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN115304607B (zh) * | 2022-07-06 | 2023-06-27 | 华南农业大学 | 吡唑并嘧啶衍生物的制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004018474A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Healthcare Ag | Phenyl-substituierte pyrazolopyrimidine |
| WO2004026876A1 (de) | 2002-08-23 | 2004-04-01 | Bayer Healthcare Ag | Alkyl-substituierte pyrazolopyrimidine |
| WO2004099211A1 (de) | 2003-05-09 | 2004-11-18 | Bayer Healthcare Ag | 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine |
| WO2008139293A1 (en) | 2007-05-11 | 2008-11-20 | Pfizer Inc. | Amino-heterocyclic compounds |
| WO2016055618A1 (en) | 2014-10-10 | 2016-04-14 | H. Lundbeck A/S | Triazolopyrazinones as pde1 inhibitors |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB973361A (en) * | 1960-05-11 | 1964-10-28 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| DE10238722A1 (de) * | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
| EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
| EP2227472A1 (en) | 2007-11-30 | 2010-09-15 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| JP5453431B2 (ja) | 2008-09-08 | 2014-03-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用 |
| AU2009322904A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| US9434730B2 (en) * | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
| RU2603140C2 (ru) | 2010-09-20 | 2016-11-20 | Айронвуд Фармасьютикалз, Инк. | Соединения имидазотриазинона |
| US20130196986A1 (en) | 2010-09-21 | 2013-08-01 | Marc Labroli | Triazolopyrazinones as p2x7 receptor antagonists |
| JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| EP2717877B1 (en) | 2011-06-10 | 2017-11-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| SG11201502728WA (en) | 2011-10-10 | 2015-05-28 | Lundbeck & Co As H | Pde9i with imidazo pyrazinone backbone |
| BR112014018199A8 (pt) | 2012-01-26 | 2021-03-02 | H Lundbeck As | inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação |
| MX357320B (es) | 2012-06-18 | 2018-07-04 | Dart Neuroscience Cayman Ltd | Compuestos de la azolopirimidina-5-(6h)-ona de piridina sustituida. |
| CA2906640C (en) | 2013-03-15 | 2021-07-20 | Intra-Cellular Therapies, Inc. | Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors |
| JP5783297B2 (ja) | 2013-08-06 | 2015-09-24 | 株式会社デンソー | 力学量センサ |
| TW201609713A (zh) * | 2013-12-19 | 2016-03-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺 |
| JP5797815B1 (ja) | 2014-06-27 | 2015-10-21 | 細田建設株式会社 | 後施工アンカー及びその施工方法 |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| WO2016042775A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| JP2018508555A (ja) | 2015-03-16 | 2018-03-29 | 大日本住友製薬株式会社 | 二環性イミダゾロ誘導体 |
| US20160311831A1 (en) | 2015-04-22 | 2016-10-27 | H. Lundbeck A/S | Imidazotriazinones as PDE1 Inhibitors |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TWI609870B (zh) | 2016-02-12 | 2018-01-01 | 美國禮來大藥廠 | Pde1抑制劑 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| JP2018076285A (ja) | 2016-09-14 | 2018-05-17 | 大日本住友製薬株式会社 | 二環性イミダゾロ誘導体を含む医薬 |
| ES2967489T3 (es) | 2016-10-18 | 2024-04-30 | H Lundbeck As | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 |
| MX2019004859A (es) | 2016-10-28 | 2019-06-20 | H Lundbeck As | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. |
| RU2019109039A (ru) | 2016-10-28 | 2020-11-30 | Х. Лундбекк А/С | Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов, предназначенные для лечения психических и/или когнитивных расстройств |
-
2017
- 2017-04-05 TW TW106111366A patent/TWI729109B/zh not_active IP Right Cessation
- 2017-04-06 US US15/481,083 patent/US20170291901A1/en not_active Abandoned
- 2017-04-07 TN TNP/2018/000321A patent/TN2018000321A1/en unknown
- 2017-04-07 RS RS20200994A patent/RS60714B1/sr unknown
- 2017-04-07 HU HUE17715943A patent/HUE050320T2/hu unknown
- 2017-04-07 MX MX2018012496A patent/MX374251B/es active IP Right Grant
- 2017-04-07 LT LTEP17715943.1T patent/LT3442975T/lt unknown
- 2017-04-07 SM SM20200446T patent/SMT202000446T1/it unknown
- 2017-04-07 ES ES17715943T patent/ES2814289T3/es active Active
- 2017-04-07 KR KR1020187029341A patent/KR20180133413A/ko not_active Ceased
- 2017-04-07 WO PCT/EP2017/058332 patent/WO2017178350A1/en not_active Ceased
- 2017-04-07 GE GEAP201914901A patent/GEAP201914901A/en unknown
- 2017-04-07 RU RU2018133391A patent/RU2018133391A/ru unknown
- 2017-04-07 HR HRP20201331TT patent/HRP20201331T1/hr unknown
- 2017-04-07 CN CN201780022870.0A patent/CN109071549B/zh not_active Expired - Fee Related
- 2017-04-07 PL PL17715943T patent/PL3442975T3/pl unknown
- 2017-04-07 CR CR20180470A patent/CR20180470A/es unknown
- 2017-04-07 MY MYPI2018001605A patent/MY194722A/en unknown
- 2017-04-07 JP JP2018550733A patent/JP7093306B2/ja not_active Expired - Fee Related
- 2017-04-07 AU AU2017250431A patent/AU2017250431B2/en not_active Ceased
- 2017-04-07 UA UAA201809742A patent/UA121925C2/uk unknown
- 2017-04-07 CA CA3020053A patent/CA3020053A1/en not_active Abandoned
- 2017-04-07 BR BR112017026278-9A patent/BR112017026278A2/pt not_active Application Discontinuation
- 2017-04-07 SG SG11201808221QA patent/SG11201808221QA/en unknown
- 2017-04-07 GE GEAP201714901A patent/GEP20207057B/en unknown
- 2017-04-07 MA MA44656A patent/MA44656B1/fr unknown
- 2017-04-07 SI SI201730387T patent/SI3442975T1/sl unknown
- 2017-04-07 DK DK17715943.1T patent/DK3442975T3/da active
- 2017-04-07 ME MEP-2020-169A patent/ME03820B/me unknown
- 2017-04-07 EP EP17715943.1A patent/EP3442975B1/en active Active
- 2017-04-07 EA EA201891897A patent/EA035197B1/ru not_active IP Right Cessation
- 2017-04-07 PE PE2018001912A patent/PE20181853A1/es unknown
- 2017-04-07 PT PT177159431T patent/PT3442975T/pt unknown
- 2017-04-10 AR ARP170100915A patent/AR108109A1/es unknown
-
2018
- 2018-08-01 US US16/051,612 patent/US10538525B2/en active Active
- 2018-09-19 DO DO2018000201A patent/DOP2018000201A/es unknown
- 2018-09-25 NI NI201800092A patent/NI201800092A/es unknown
- 2018-09-26 ZA ZA2018/06407A patent/ZA201806407B/en unknown
- 2018-09-26 CO CONC2018/0010323A patent/CO2018010323A2/es unknown
- 2018-09-28 SV SV2018005753A patent/SV2018005753A/es unknown
- 2018-10-03 EC ECSENADI201874641A patent/ECSP18074641A/es unknown
- 2018-10-09 PH PH12018502168A patent/PH12018502168A1/en unknown
- 2018-10-10 CL CL2018002881A patent/CL2018002881A1/es unknown
- 2018-10-10 IL IL262257A patent/IL262257B/en active IP Right Grant
-
2019
- 2019-12-03 US US16/701,269 patent/US11104680B2/en not_active Expired - Fee Related
-
2020
- 2020-08-20 CY CY20201100779T patent/CY1123269T1/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004018474A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Healthcare Ag | Phenyl-substituierte pyrazolopyrimidine |
| WO2004026876A1 (de) | 2002-08-23 | 2004-04-01 | Bayer Healthcare Ag | Alkyl-substituierte pyrazolopyrimidine |
| WO2004099211A1 (de) | 2003-05-09 | 2004-11-18 | Bayer Healthcare Ag | 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine |
| WO2008139293A1 (en) | 2007-05-11 | 2008-11-20 | Pfizer Inc. | Amino-heterocyclic compounds |
| WO2016055618A1 (en) | 2014-10-10 | 2016-04-14 | H. Lundbeck A/S | Triazolopyrazinones as pde1 inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| FINLANDER, P et al.，Phosphorus Pentoxide in Organic Synthesis，Chemica Scripta，1983年，Vol. 22，pp. 171-176 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7093306B2 (ja) | ＰＤＥ１阻害剤としての１，５－ジヒドロ－４Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－４－オン及び１，５－ジヒドロ－４Ｈ－ピラゾロ［４，３－ｃ］ピリジン－４－オン | |
| JP6596489B2 (ja) | Ｐｄｅ１阻害剤としてのトリアゾロピラジノン | |
| JP5542196B2 (ja) | １−複素環−１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｐｄｅ９ａモジュレーターとしてのそれらの使用 | |
| CA3015484A1 (en) | Novel condensed pyrimidine compound or salt thereof | |
| TWI707855B (zh) | 咪唑并嗒類化合物及其用途 | |
| US20120010224A1 (en) | 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolepyrimidines | |
| EA021504B1 (ru) | Производные 1-гетероциклил-1,5-дигидропиразоло[3,4-d]пиримидин-4-она и их применение в качестве модуляторов pde9a | |
| JP2013515734A (ja) | ポロ様キナーゼの阻害薬としてのプテリジノン | |
| AU2004235915B2 (en) | 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines | |
| CN101917995A (zh) | Polo样激酶抑制剂 | |
| JP4889480B2 (ja) | ６−アリールメチル置換ピラゾロピリミジン類 | |
| JP2015522557A (ja) | タンキラーゼのピロロピリミドン及びピロロピリドン阻害剤 | |
| TW201639845A (zh) | 新的雜芳基和雜環化合物、其組成物及方法 | |
| JP5277303B2 (ja) | ６−シクリルメチル−および６−アルキルメチル置換ピラゾロピリミジン類 | |
| HK40001748A (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
| HK40001748B (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
| HK1232524A1 (en) | Novel imidazopyridazine compounds and their use | |
| HK1232524B (zh) | 新的咪唑并哒嗪类化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200327 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200327 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210210 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210309 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210604 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220204 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220607 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220617 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7093306 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |